Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'Healthy People 2020' Should Adopt Evidence Classification Scheme - Report

This article was originally published in The Gray Sheet

Executive Summary

An advisory committee involved in development of the Department of Health and Human Services' "Healthy People 2020" initiative is recommending an approach to implementing the initiative's objectives based on four levels of evidence-based criteria

You may also be interested in...



HHS Gives Nod To Diagnostics In Healthy People 2020 Initiative

More people would be screened for health conditions ranging from diabetes to colorectal cancer to sleep apnea over the next decade under goals set out in HHS’ recent “Healthy People 2020” initiative.

HHS Gives Nod To Diagnostics In Healthy People 2020 Initiative

More people would be screened for health conditions ranging from diabetes to colorectal cancer to sleep apnea over the next decade under goals set out in HHS’ recent “Healthy People 2020” initiative.

Research In Brief

Ischemia diagnostic study: Cambridge Heart has initiated a 200-patient study to evaluate microvolt T-wave alternans testing in detection of ischemia in patients with known or suspected coronary artery disease, the firm announced July 6. The company is hoping to show that MTWA, which allows real-time intra-cardiac measurements of heart rhythm irregularities, can enhance the diagnosis of underlying ischemia; currently, the test, conducted on its HearTwave II system, is used to assess the risk of potentially fatal arrhythmias. Enrollment in the trial is expected to wrap up in mid-2011. "If the results of the pilot study confirm our finding, we will begin a larger study [in] the second half of 2011," according to Cambridge Heart CEO Ali Haghighi-Mood. The firm announced it had licensed the patent for the incorporation of MWTA in implantable medical devices from MIT in 2008 (1"The Gray Sheet" June 30, 2008)

Related Content

Topics

UsernamePublicRestriction

Register

MT029194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel